Compare Inovio Pharmaceuticals Inc (INO) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ProShares Ultra Gold ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while ProShares Ultra Gold ETF trades at $46.37 (market cap $716.59M). The key difference: ProShares Ultra Gold ETF is far larger — about 6.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and ProShares Ultra Gold ETF for 23 Days on average.
| INO | UGL | |
|---|---|---|
Market Cap | $112.19M | $716.59M |
Volume | 3,201,278 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.65 | $85.62 |
52-Week Low | $0.66 | $42.79 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
UGL trades at $46.24, up 4.07% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $46 and support at $45. Financial ratios are unavailable, limiting fundamental assessment. Recent gold-related news highlights volatility from Treasury yields and Fed policy, influencing sentiment.
Outlook remains cautious due to bearish technicals and macroeconomic pressures. Risks include interest rate sensitivity and lack of financial transparency. Investors should await earnings reports for fundamental clarity amid current market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
